.svg)
Alameda, Calif. – February 27 - 2024 – Alveo Technologies, Inc. (Alveo), a leader in molecular sensing and diagnostics with proprietary molecular detection platform technology, today announced highlights of the success of its open platform approach and partnering initiative over 2023 and its momentum going into 2024.
Alveo’s core technology is a rapid, handheld, reusable, and rugged multiplexed molecular diagnostic platform that pairs with its mobile apps, be.well (human applications), and Alveo Sense (non-human applications). The platform combines advanced molecular assays with cloud-enabled data analytics to provide highly accurate and sensitive detection, analysis, and diagnosis of diseases, pathogens, and contaminants. This portable molecular lab can deliver rapid test results at the point-of-need or in the field. Alveo’s platform also provides geo-tagged results that can be uploaded to the cloud to give a real-time view of national outbreaks and better inform response.
The platform has already been used to develop a rapid, accurate, point-of-care COVID-19 test, which is currently on the market in EMEA. Alveo identified great potential for their proprietary and unique platform beyond the human health applications for which it was originally developed. This recognition of the wider opportunity led to the establishment of a partnership program in July, enabling innovators across many industries — including agriculture, food safety, biomanufacturing, and veterinary to name a few — to co-develop multiplexed panels for testing of pathogens unique to each industry or specific to that partner. In addition, a key component to the partnership program driving seamless enablement, Alveo developed Impedance Analysis and Configuration Tools (IMPACTTM), a software suite of tools to further accelerate co-development.
Within months of launching the program, Alveo announced key partnerships with industry leaders including Corteva Agriscience, who is focused on designing crop-specific assays to detect pathogens in the field using Alveo's highly sensitive multiplexed testing platform. Alveo also forged an agreement to develop crop assays with Fraunhofer Institute for Cell Therapy and Immunology IZI to detect botrytis, a fungus that affects a wide range of fruits and vegetables and causes more than $10 billion in economic damage worldwide.
In December, Alveo announced a major expansion of its Human & Animal Health distribution network in EMEA, signing on new distributors across the entire region. These agreements have proven crucial to meeting the rapidly growing demand for accurate rapid infectious disease testing at the point of care.
Most recently, Alveo unveiled partnerships with x-OvO, Royal GD, and Pharmsure to co-develop and distribute a groundbreaking multiplexed panel of accurate, rapid, in-field tests for highly pathogenic avian influenza (HPAI), focused initially on Group A, H5, H7, and H9. Alveo expects to release the Flockscreen™ LAMP AI assays in EMEA in the first half of this year.
Looking ahead, Alveo expects to announce additional partnerships with veterinary, food safety, biomanufacturing, and agricultural companies to further expand applications on the Alveo platform. Alveo is also currently developing diagnostic tests for additional applications in human health, including multiplexed assays that, in a single handheld test device, can detect the presence of several pathogens.
“In 2023, Alveo saw an enormous opportunity to partner with leading veterinary and agricultural companies to co-develop assays on our platform to address a wide range of challenges in those particular markets,” said Shaun Holt, CEO of Alveo. “The partner program has been even more successful than we expected in its first six months, and the momentum we built last year is already carrying Alveo to bigger things in 2024.”
About Alveo
Alveo is the first company to make molecular detection and diagnostics universally accessible – on the farm, in the field, in the clinic, or in the manufacturing plant – helping prevent or significantly limit the destructive impact of viruses, fungi, bacteria, and other pathogens by detecting earlier at the point of need. Alveo’s rugged and portable, multiplex-capable diagnostic platform employs a patented method of direct electrical sensing of nucleic acid amplification to provide affordable, rapid, and accurate results. By enabling early pathogen detection, Alveo helps manage global health, food security, and supply chain resiliency by providing actionable insights at lightspeed. Know Sooner, Act Faster™ with Alveo. For more, For more, visit: https://www.alveotechnologies.com/
